Therefore, targeting TLK1, in combination with other therapeutic modalities, to disrupt the TLK1>AKTIP>AKT pathway and impair AKT activation could sensitize the PCa cells to apoptotic death and inhibit lethal CRPC progression. This evidence concerns the gene AKT1 and posterior cortical atrophy.